NEW YORK and SANTA BARBARA, Calif., July 30, 2024 - Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck. The updated presentation provides an in-depth look at the company’s strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. The...
Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential
read more